<DOC>
	<DOCNO>NCT02714595</DOCNO>
	<brief_summary>This study design provide evidence efficacy S-649266 treatment serious infection adult patient cause carbapenem-resistant Gram-negative pathogen .</brief_summary>
	<brief_title>Study S-649266 Best Available Therapy Treatment Severe Infections Caused Carbapenem-resistant Gram-negative Pathogens</brief_title>
	<detailed_description>This study design provide evidence efficacy S-649266 treatment serious infection adult patient either hospital-acquired pneumonia ( HAP ) /ventilator-associated pneumonia ( VAP ) /healthcare-associated pneumonia ( HCAP ) , complicate urinary tract infection ( cUTI ) , bloodstream infection ( BSI ) /sepsis cause carbapenem-resistant Gram-negative pathogen .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<criteria>Patients clinically document infection ( HAP/VAP/HCAP , cUTI , BSI/sepsis ) cause Gramnegative pathogen evidence carbapenem resistance Patients treat previously empiric antibiotic regiment fail treatment , clinically microbiologically , eligible study , identify carbapenemresistant Gramnegative pathogen either show nonsusceptible vitro antibiotic ( ) empiric antibiotic regimen grown culture perform least two day empiric antibiotic regimen Patient male ( contraception require ) female meet one follow criterion : Surgically sterile hysterectomy and/or bilateral oophorectomy bilateral salpingectomy tubal ligation purpose contraception least 6 week appropriate documentation surgery Postmenopausal ( define old 45 year age cessation regular menstrual period 6 month confirm folliclestimulating hormone level &gt; 40 mIU/ml , amenorrhea least 12 month ) Of childbearing potential use combine ( estrogen progestogen ) progestogenonly hormonal contraception associate inhibition ovulation ( include oral , intravaginal , injectable , implantable , transdermal contraceptive ) , intrauterine device ( IUD ) , intrauterine hormonereleasing system ( IUS ) entire duration study Of childbearing potential practice abstinence prefer usual lifestyle , agree continue practice abstinence screen 14 day last dose study drug Of childbearing potential , whose sole heterosexual partner successfully vasectomize agree heterosexual partner entire duration study Patients meet specific criterion infection site 1 . Patients document history moderate severe hypersensitivity allergic reaction βlactam ( Note : βlactams , history mild rash follow uneventful reexposure contraindication enrollment ) 2 . Patients need 3 systemic antibiotic part best available therapy ( BAT ) treatment Gramnegative infection ( patient mixed Grampositive anaerobic infection may receive appropriate concomitant narrow spectrum antibiotic [ eg , vancomycin , linezolid , metronidazole , clindamycin ] ) 3 . Patients coinfection cause invasive aspergillosis , mucormycosis highly lethal mold 4 . Patients central nervous system ( CNS ) infection ( eg , meningitis , brain abscess , shunt infection ) 5 . Patients infection require &gt; 3 week antibiotic treatment ( eg , bone joint infection , endocarditis ) 6 . Patients cystic fibrosis bronchiectasis 7 . Patients refractory septic shock define persistent hypotension despite adequate fluid resuscitation despite vasopressive therapy time Randomization 8 . Patients severe neutropenia , ie , polymorphonuclear neutrophil ( PMNs ) &lt; 100 cells/μL 9 . Female patient positive pregnancy test Screening lactate 10 . Patients Acute Physiology Chronic Health Evaluation II ( APACHE II ) score &gt; 30 11 . Patients receive potentially effective antibiotic regimen carbapenemresistant Gramnegative infection continuous duration 24 hour cUTI , 36 hour HAP/VAP/HCAP BSI/sepsis 72 hour lead Randomization 12 . Patients condition circumstance , opinion investigator , would compromise safety patient quality study data 13 . Patients require continue treatment methotrexate , procainamide , probenecid 14 . Patients receive another investigational drug device within 30 day prior study entry 15 . Patients previously randomize study receive S649266 16 . Patients receive peritoneal dialysis 17 . Patients meet specific exclusion criterion infection site</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>cefiderocol</keyword>
	<keyword>Bloodstream infection ( BSI )</keyword>
	<keyword>Complicated urinary tract infection ( cUTI )</keyword>
	<keyword>Ventilator associate pneumonia ( VAP )</keyword>
	<keyword>Hospital acquire pneumonia ( HAP )</keyword>
	<keyword>Sepsis</keyword>
	<keyword>multi-drug resistant pathogen</keyword>
	<keyword>S-649266</keyword>
	<keyword>Gram-negative pathogen</keyword>
	<keyword>Healthcare-associated pneumonia ( HCAP )</keyword>
	<keyword>carbapenem resistant pathogen</keyword>
</DOC>